Skip to main content

Table 2 Effect of treatment for PAG compared with AG on PFS for the ECM biomarkers using the median cut-off point in stage 1 of HALO 109-202

From: Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa

Biomarker subgroup HR 95% CI P-value
C3M low 0.74 0.47–1.16 0.192
C3M high 0.70 0.33–1.45 0.332
C8-Ca low 0.72 0.38–1.38 0.323
C8-Ca high 0.56 0.21–1.45 0.231
PRO-C3 low 0.53 0.23–1.20 0.130
PRO-C3 high 0.88 0.43–1.80 0.735
PRO-C6 low 0.47 0.21–1.08 0.077
PRO-C6 high 1.07 0.53–2.17 0.853
VCANMb low 0.63 0.32–1.23 0.176
VCANMb high 0.73 0.30–1.74 0.725
C3M/PRO-C3 ratio low 1.09 0.55–2.18 0.807
C3M/PRO-C3 ratio high 0.40 0.17–0.92 0.031*
  1. aDetectable in 33% of samples
  2. bDetectable in 37% of samples
  3. A univariate Cox regression analysis was used to calculate the predictive associations between biomarker levels and PFS. *A significant PFS benefit for PAG compared with AG was observed in the C3M/PRO-C3 ratio high subgroup (HR 0.40; 95% CI 0.17–0.92; P = .031). All other associations were non-significant